share_log

HC Wainwright & Co. Initiates Coverage On TransCode Therapeutics with Buy Rating, Announces Price Target of $10

Benzinga Real-time News ·  Jun 7, 2022 06:24

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on TransCode Therapeutics (NASDAQ:RNAZ) with a Buy rating and announces Price Target of $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment